Iberia Pharmaceuticals scores big with KeyCi launch, signals shift towards science-backed skincare

KeyCi’s dermatologically tested lineup emphasizes clean formulations—vegan, cruelty-free, alcohol-free, and paraben-free—while being backed by pharmaceutical-grade research and FDA approval

Pfizer warns shareholders against Tutanota’s mini-tender offer

Pfizer recommends that shareholders do not tender their shares in response to Tutanota’s offer

Rhythm Pharmaceuticals’ Phase 3 EMANATE trial falls short of primary goals

The study included four independent genetic substudies targeting obesity caused by heterozygous variants in the POMC/PCSK1, LEPR, SRC1 (NCOA1), and SH2B1 genes

Eli Lilly’s experimental drug Retatrutide shows major breakthrough in Type 2 diabetes trial

Pfizer drug candidate shows strong results in tough breast cancer study

The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged

Trial milestone sparks hope for first long-term gastroparesis treatment

The Phase 2 envisionGI study is testing deudomperidone, an experimental drug aimed at treating idiopathic gastroparesis

Merck’s SPARK program hits 10-year milestone, sets sights on reaching 75 million students

SPARK has extended its influence to an additional 9.47 million students worldwide

Novartis’ Cosentyx gains FDA nod for pediatric hidradenitis suppurativa patients

The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options

Sun Pharma scores FDA review for ILUMYA in psoriatic arthritis

ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025

Lilly expands access to Zepbound weight-loss drug with $299 monthly self-pay option

The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect